A double-blind, crossover study of acebutolol and hydrochlorothiazide/amiloride diuretic in Sudanese patients with essential hypertension.
A double-blind, crossover study was carried out in 32 Sudanese patients with essential hypertension to assess the effectiveness of single daily doses of 400 mg acebutolol when given alone and in combination with single daily doses of hydroclorothiazide/amiloride diuretic. The results show that in both groups there was a statistically significant reduction in systolic and diastolic levels throughout the treatment period. After crossover at 6 weeks, those patients initiated on acebutolol alone showed a further reduction in both systolic and diastolic pressures when the hydrochlorothiazide/amiloride combination was added. Both treatment regimens were well-tolerated and only a few side-effects were reported.
D000070:Acebutolol / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000584:Amiloride / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011674:Pulse / Q000187:drug effects; D011719:Pyrazines / Q000627:therapeutic use*; D013397:Sudan
D011719:Pyrazines; D006852:Hydrochlorothiazide; D000070:Acebutolol; D000584:Amiloride